PRDX2 and non-small cell lung carcinoma: For instance, PRDX2 silencing has been shown to inhibit proliferation and invasion in non-small cell lung cancer cells [14,40], promote growth, survival, and resistance to cisplatin in gastric cancer cells [11,15] and impair proliferation, cell cycle, and autophagy in colorectal cancer cells [11,16].